Proservice Bldg Regulatory News (PRO)

3 Aug 2005 07:00

Provalis PLC03 August 2005 Provalis plc in2it(TM)A1c achieves NGSP Certification and Brand Creation Award Provalis plc (LSE: PRO; NASDAQ: PVLS), the international medical diagnostics andpharmaceuticals group, is pleased to announce that in2it(TM)A1c, its flagshipdiabetes diagnostic product, has been certified by the National GlycohaemoglobinStandardisation Program (NGSP). NGSP is an independent quality assessment run by the University of Missouri. Theimportance of the certification is such that the American Diabetes Associationonly recommends, and many health care providers in the USA will only use, teststhat are NGSP certified. During the last few months Provalis has begun to build brand awareness of in2it(TM)A1c in the USA and is delighted to announce that its campaign in 2005 haswon first place in the recent Bio-medical Marketing Association Awards in thecategory of Product Brand Creation. Phil Gould, Chief Executive Officer of Provalis, said "NGSP certification shows that in2it(TM) has achieved the gold standard inindependent technical assessments. This certification, coupled with increasingproduct awareness, will accelerate sales of in2it(TM) in the USA". 3 August 2005For further information:- Provalis plcDr Phil Gould, Chief Executive Officer 01244 833463Mr Peter Bream, Finance Director 01244 833552Mr Lee Greenbury, Company Secretary 01244 833402 College HillAdrian Duffield 020 7457 2815Corinna Dorward 020 7457 2803 Notes to Editors Provalis plc (LSE: PRO; NASDAQ: PVLS) is an international healthcare group withtwo operating businesses:- • Medical Diagnostics - The business' principal products are in2it (TM)A1c and Glycosal(R), both diabetes diagnostic tests. In2it(TM)A1c is a fully automated, point of care, diabetes diagnostic, testing platform which has marketing clearance from the FDA in the US for use in both physicians' offices and at home on prescription. • Pharmaceuticals - sells and markets its own, and third party, branded, prescription medicines in the UK and Ireland to GPs and hospitals through its regionally managed sales force. The business' principal product is Diclomax(R), a medicine for use in the treatment of musculo-skeletal disorders, and it also sells products in the areas of osteoporosis, migraine and dermatology. Visit Provalis' Revised Website at http://www.provalis.com "Safe Harbor" Statement under the US Private Securities Litigation Reform Act of1995: Statements in this announcement that relate to future plans, expectations,events, performances and the like are forward-looking statements as defined inthe US Private Securities Litigation Reform Act of 1995. Actual results ofevents could differ materially from those described in the forward-lookingstatements due to a variety of factors. Such factors include, among others: theviability of the Group's products, which are at various stages of development;the generation of sufficient operating cash flow by the Group's pharmaceuticaland medical diagnostic businesses to finance the ongoing development of thesebusinesses as well as the Group's research and development activities; thesuccess of the Group's research and development strategy and activities;uncertainties related to future clinical trial results and the associatedregulatory process; the execution and success of collaborative agreements withthird parties; availability and level of reimbursement for the Group's productsfrom government health administration authorities or other third-party payors;the rate of net cash utilisation within the Group and, hence, the Group'spossible need for additional capital in the short, medium and/or long term; theGroup's intellectual property position and the success of patent applicationsfor its products and technologies; the Group's dependence on key personnel;general business and economic conditions; the impact of future laws, regulationsand policies; stock market trends in the Group's sector; and other factorsbeyond the Group's control that may cause the Group's available capitalresources to be used more quickly than expected. These and other factors thatcould affect the Company's future results are more fully described in itsfilings with the US Securities and Exchange Commission, in particular the latest20-F filing, copies of which are available from the Company Secretary at theCompany's registered address. This information is provided by RNS The company news service from the London Stock Exchange